Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Cancers
|
July 29, 2025
The Real-World Efficacy and Side Effects of Different Nivolumab Regimens in Japanese Patients with Advanced Melanoma: A Single-Center Retrospective Study
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology
|
May 23, 2025
Predictors of Dermal Invasion and Sentinel Lymph Node Metastasis in Patients With Extramammary Paget's Disease Without Clinical Lymph Node Enlargement
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology
|
October 7, 2025
C-Reactive Protein Kinetics as Prognostic Biomarkers in Stage IV-Melanoma Treated With Immune Checkpoint Inhibitors in the Japanese Population: A Single-Center, Retrospective Cohort Study
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology
|
January 7, 2026
Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Stage IV Melanoma Receiving Immune Checkpoint Inhibitors: A Single-Center Retrospective Study
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
Melanoma Research
|
December 4, 2024
Clinical features of vulvar and vaginal malignant melanomas and the effects of immune checkpoint inhibitors in Japanese patients: a single-center, retrospective cohort study
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology
|
September 13, 2024
Comparison of efficacy between anti-PD-1 antibody monotherapy and nivolumab plus ipilimumab therapy as first-line immunotherapy for advanced mucosal melanoma in Japanese patients: A single-center, retrospective cohort study
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology
|
September 6, 2025
Prognosis and Toxicity Stratified by Best Tumor Burden Change in Japanese Patients With Advanced Melanoma Treated With First-Line Programmed Cell Death Protein 1 Monotherapy
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology
|
March 5, 2025
Comparison of efficacy and adverse events by treatment cycles of nivolumab and ipilimumab in Japanese melanoma patients: A single-center, retrospective study
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology
|
February 7, 2025
Prognostic value of the CONUT score with immune checkpoint inhibitors as first-line therapy for metastatic malignant melanoma
Ken Horisaki, Shusuke Yoshikawa, Shoichiro Mori, et al.
Case Reports in Dermatology
|
May 2, 2022
Secondary Adrenal Insufficiency in a Patient with Metastatic Melanoma Treated with Nivolumab
Wataru Omata, Satoko Nakamura, Chie Urasaki, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Cancers
|
July 29, 2025
The Real-World Efficacy and Side Effects of Different Nivolumab Regimens in Japanese Patients with Advanced Melanoma: A Single-Center Retrospective Study
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology
|
May 23, 2025
Predictors of Dermal Invasion and Sentinel Lymph Node Metastasis in Patients With Extramammary Paget's Disease Without Clinical Lymph Node Enlargement
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology
|
October 7, 2025
C-Reactive Protein Kinetics as Prognostic Biomarkers in Stage IV-Melanoma Treated With Immune Checkpoint Inhibitors in the Japanese Population: A Single-Center, Retrospective Cohort Study
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology
|
January 7, 2026
Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Stage IV Melanoma Receiving Immune Checkpoint Inhibitors: A Single-Center Retrospective Study
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
Melanoma Research
|
December 4, 2024
Clinical features of vulvar and vaginal malignant melanomas and the effects of immune checkpoint inhibitors in Japanese patients: a single-center, retrospective cohort study
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology
|
September 13, 2024
Comparison of efficacy between anti-PD-1 antibody monotherapy and nivolumab plus ipilimumab therapy as first-line immunotherapy for advanced mucosal melanoma in Japanese patients: A single-center, retrospective cohort study
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology
|
September 6, 2025
Prognosis and Toxicity Stratified by Best Tumor Burden Change in Japanese Patients With Advanced Melanoma Treated With First-Line Programmed Cell Death Protein 1 Monotherapy
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology
|
March 5, 2025
Comparison of efficacy and adverse events by treatment cycles of nivolumab and ipilimumab in Japanese melanoma patients: A single-center, retrospective study
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology
|
February 7, 2025
Prognostic value of the CONUT score with immune checkpoint inhibitors as first-line therapy for metastatic malignant melanoma
Ken Horisaki, Shusuke Yoshikawa, Shoichiro Mori, et al.
Case Reports in Dermatology
|
May 2, 2022
Secondary Adrenal Insufficiency in a Patient with Metastatic Melanoma Treated with Nivolumab
Wataru Omata, Satoko Nakamura, Chie Urasaki, et al.
Page
of 2